{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T14:01:53Z","timestamp":1782828113972,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["420381\/2018-0"],"award-info":[{"award-number":["420381\/2018-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s10787-021-00822-x","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T17:25:55Z","timestamp":1622136355000},"page":"595-615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Current jakinibs for the treatment of rheumatoid arthritis: a systematic review"],"prefix":"10.1007","volume":"29","author":[{"given":"Cl\u00e1udia Monfroni","family":"Rocha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Menna","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz Fabris","family":"Bettanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Majolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Gehringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Laufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3648-5033","authenticated-orcid":false,"given":"M\u00e1rcia In\u00eas","family":"Goettert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,27]]},"reference":[{"key":"822_CR1","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/annrheumdis-2015-208267","volume":"75","author":"PG Conaghan","year":"2016","unstructured":"Conaghan PG, \u00d8stergaard M, Bowes MA, Wu C, Fuerst T, van der Heijde D, Irazoque-Palazuelos F, Soto-Raices O, Hrycaj P, Xie Z, Zhang R, Wyman BT, Bradley JD, Soma K, Wilkinson B (2016) Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Ann Rheum Dis 75:1024\u20131033","journal-title":"Ann Rheum Dis"},{"key":"822_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1590\/S0482-50042011000300002","volume":"51","author":"LMH da Mota","year":"2011","unstructured":"da Mota LMH, Cruz BA, Brenol CV, Pereira IA, Fronza LSR, Bertolo MB, de Freitas MVC, Silva NA, Louzada-Junior P, Giorgi RDN, Lima RAC, Pinheiro GRC (2011) Consenso Da Sociedade Brasileira de Reumatologia 2011 Para o Diagn\u00f3stico e Avalia\u00e7\u00e3o Inicial Da Artrite Reumatoide. Rev Bras Reumatol 51:207\u2013219","journal-title":"Rev Bras Reumatol"},{"key":"822_CR2","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, Zerbini CA, Gurbuz S, Dickson C, de Bono S, Schlichting D, Beattie S, Kuo WL, Rooney T, Macias W, Takeuchi T (2017) Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis and Rheumatol 69:506\u2013517","journal-title":"Arthritis and Rheumatol"},{"key":"822_CR3","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/art.38949","volume":"67","author":"RM Fleischmann","year":"2015","unstructured":"Fleischmann RM, Damjanov NS, Kivitz AJ, Legedza A, Hoock T, Kinnman N (2015) A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. Arthritis Rheumatol 67:334\u2013343","journal-title":"Arthritis Rheumatol"},{"key":"822_CR4","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1002\/art.39808","volume":"68","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Smolen JS, Weinblatt ME, Burmester GR, Meerwein S, Camp HS, Wang L, Othman AA, Khan N, Pangan AL, Jungerwirth S (2016a) Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol 68:2857\u20132866","journal-title":"Arthritis Rheumatol"},{"key":"822_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/art.39473","volume":"68","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, van Vollenhoven RF, Pacheco-Tena C, Zhang Y, Kinnman N (2016b) VX-509 (Decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol 68:46\u201355","journal-title":"Arthritis Rheumatol"},{"key":"822_CR6","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/art.40054","volume":"69","author":"MC Genovese","year":"2017","unstructured":"Genovese MC, Greenwald M, Codding C, Zubrzycka-Sienkiewicz A, Kivitz AJ, Wang A, Shay K, Wang X, Garg JP, Cardiel MH (2017) Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol 69:932\u2013942","journal-title":"Arthritis Rheumatol"},{"key":"822_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, Gao J, Guo Y, Tasset C, Sundy JS, de Vlam K, Walker D, Takeuchi T (2019) Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA 322:315\u2013325","journal-title":"JAMA"},{"key":"822_CR9","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1093\/rheumatology\/kes367","volume":"52","author":"V Kelly","year":"2013","unstructured":"Kelly V, Genovese M (2013) Novel small molecule therapeutics in rheumatoid arthritis. Rheumatology (oxford) 52:1155\u20131162","journal-title":"Rheumatology (oxford)"},{"key":"822_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/art.39955","volume":"69","author":"AJ Kivitz","year":"2017","unstructured":"Kivitz AJ, Gutierrez-Ure\u00f1a SR, Poiley J, Genovese MC, Kristy R, Shay K, Wang X, Garg JP, Zubrzycka-Sienkiewicz A (2017) Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate. Arthritis Rheumatol 69:709\u2013719","journal-title":"Arthritis Rheumatol"},{"key":"822_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1759720X18776224","volume":"10","author":"CJ Malemud","year":"2018","unstructured":"Malemud CJ (2018) The role of the JAK\/STAT signal pathway in rheumatoid arthritis. Ther Adv Musculoskelet Dis 10:117\u2013127","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"822_CR13","first-page":"1","volume":"8","author":"H Pei","year":"2018","unstructured":"Pei H, He L, Shao M, Yang Z, Ran Y, Li D, Zhou Y, Tang M, Wang T, Gong Y, Chen X, Yang S, Xiang M, Chen L (2018) Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis. Sci Rep 8:1","journal-title":"Sci Rep"},{"key":"822_CR14","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, Zhang Y, Damjanov N, Friedman A, Othman AA, Camp HS, Cohen S (2019) Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 393:2303\u20132311","journal-title":"Lancet"},{"key":"822_CR15","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","volume":"75","author":"T Takeuchi","year":"2016","unstructured":"Takeuchi T, Tanaka Y, Iwasaki M, Ishikura H, Saeki S, Kaneko Y (2016) Efficacy and safety of the oral janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis 75:1057\u20131064","journal-title":"Ann Rheum Dis"},{"key":"822_CR16","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","volume":"78","author":"T Takeuchi","year":"2019","unstructured":"Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Iwasaki M, Katayama K, Rokuda M, Izutsu H, Ushijima S, Kaneko Y, Shiomi T, Yamada E, van der Heijde D (2019) Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis 78:1305\u20131319","journal-title":"Ann Rheum Dis"},{"key":"822_CR17","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3899\/jrheum.150613","volume":"43","author":"Y Tanaka","year":"2016","unstructured":"Tanaka Y, Emoto K, Cai Z, Aoki T, Schlichting D, Rooney T, Macias W (2016) Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol 43:504\u2013511","journal-title":"J Rheumatol"},{"key":"822_CR18","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","volume":"78","author":"Y Tanaka","year":"2019","unstructured":"Tanaka Y, Takeuchi T, Tanaka S, Kawakami A, Iwasaki M, Song YW, Chen YH, Wei JC, Lee SH, Rokuda M, Izutsu H, Ushijima S, Kaneko Y, Akazawa R, Shiomi T, Yamada E (2019) Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled Phase III trial (RAJ3). Ann Rheum Dis 78:1320\u20131332","journal-title":"Ann Rheum Dis"},{"key":"822_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.5114\/reum.2020.102006","volume":"58","author":"I Urits","year":"2020","unstructured":"Urits I, Israel J, Hakobyan H, Yusin G, Lassiter G, Fackler N, Berger A, Kassem H, Kaye A, Viswanath O (2020) Baricitinib for the treatment of rheumatoid arthritis. Reumatologia Rheumatology 58:407\u2013415","journal-title":"Reumatologia Rheumatology"},{"key":"822_CR8","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/art.40803","volume":"71","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Strand V, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardiel MH, Cohen S, Nash P, Song YW, Tegzov\u00e1 D, Gruben D, Wallenstein G, Connell CA, Fleischmann R (2019) Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty-four\u2013month, phase III study. Arthritis Rheumatol 71:878\u2013891","journal-title":"Arthritis Rheumatol"},{"key":"822_CR20","first-page":"1","volume":"22","author":"WC Yi","year":"2021","unstructured":"Yi WC, Yang HY, Luo SF, Lai JH (2021) From rheumatoid factor to anti-citrullinated protein antibodies and anti-carbamylated protein antibodies for diagnosis and prognosis prediction in patients with rheumatoid arthritis. Int J Mol Sci 22:1\u201318","journal-title":"Int J Mol Sci"},{"key":"822_CR21","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12016-020-08786-6","volume":"5","author":"H You","year":"2020","unstructured":"You H, Xu D, Zhao J, Li J, Wang Q, Tian X, Li M, Zeng X (2020) JAK inhibitors: prospects in connective tissue diseases. Clin Rev Allergy Immunol 5:334\u2013351","journal-title":"Clin Rev Allergy Immunol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-021-00822-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-021-00822-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-021-00822-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T10:17:01Z","timestamp":1624616221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-021-00822-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,27]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["822"],"URL":"https:\/\/doi.org\/10.1007\/s10787-021-00822-x","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,27]]},"assertion":[{"value":"28 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no professional affiliation, financial interest or conflict with the subject matter or information discussed here in this manuscript to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}